Answers are grounded in this paper and cite their sources.
Cancer patients with COVID-19 disease are at increased risk of mortality and morbidity. A more nuanced understanding of the interaction between cancer-directed therapies and COVID-19-directed therapies is needed. This will require uniform prospective recording of data, possibly in multi-institutional registry databases.
No takes yet. Share an insight, caveat, or question.
Venkatesulu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: